KMKanishka Manna

Kanishka Manna

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kanishka Manna has a total of 25 co-authors. Here are the top co-authors by number of shared publications:

  • Duah Alkam

    Department of Biochemistry and Molecular Biology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences

    2 shared publications
  • Stephanie D. Byrum

    Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA

    2 shared publications
  • Alan Jackson Tackett

    Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA

    1 shared publication
  • Alicia K Byrd

    Winthrop P. Rockefeller Cancer Institute, 449 Jack Stephens Dr d , Little Rock, AR 72205, USA

    1 shared publication
  • Allen Gies

    Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences a , 4301 West Markham Street (slot 516), Little Rock, AR 72205-7199, USA+(501) 526-7008 +(501) 686-5783

    1 shared publication
  • Charity L. Washam

    Arkansas Children's Research Institute, 13 Children's Way b , Little Rock, AR 72202, USA

    1 shared publication

Latest Publications

  • Open Access

    Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy

    by Kanishka Manna, Prashanthi Dharanipragada, Duah Alkam, Nathan L. Avaritt, Charity L. Washam, Michael S. Robeson, Ricky D. Edmondson, Samuel G. Mackintosh, Zhentao Yang, Yan Wang, et al.

    Therapeutic approaches to treat melanoma include small molecule drugs that target activating protein mutations in pro-growth signaling pathways like the MAPK pathway. While beneficial to the approximately 50% of patients with activating BRAF V600 mutation, mono- and combination therapy with MAPK inhibitors is ultimately associated with acquired resistance. To better characterize the mechanisms of MAPK inhibitor resistance in melanoma, we utilize patient-derived xenografts and apply proteogenomic approaches leveraging genomic, transcriptomic, and proteomic technologies that permit the identification of resistance-specific alterations and therapeutic vulnerabilities. A specific challenge for proteogenomic applications comes at the level of data curation to enable multi-omics data integration. Here, we present a proteogenomic approach that uses custom curated databases to identify unique resistance-specific alternations in melanoma PDX models of acquired MAPK inhibitor resistance. We demonstrate this approach with a NRAS Q61L melanoma PDX model from which resistant tumors were developed following treatment with a MEK inhibitor. Our multi-omics strategy addresses current challenges in bioinformatics by leveraging development of custom curated proteogenomics databases derived from individual resistant melanoma that evolves following MEK inhibitor treatment and is scalable to comprehensively characterize acquired MAPK inhibitor resistance across patient-specific models and genomic subtypes of melanoma.

  • Open Access

    Multi-omics data integration reveals correlated regulatory features of triple negative breast cancer

    by Kevin Chappell, Kanishka Manna, Charity L. Washam, Stefan Graw, Duah Alkam, Matthew D. Thompson, Maroof Khan Zafar, Lindsey Hazeslip, Christopher Randolph, Allen Gies, et al.

    Triple negative breast cancer (TNBC) is an aggressive type of breast cancer with very little treatment options. TNBC is very heterogeneous with large alterations in the genomic, transcriptomic, and proteomic landscapes leading to various subtypes with differing responses to therapeutic treatments. We applied a multi-omics data integration method to evaluate the correlation of important regulatory features in TNBC BRCA1 wild-type MDA-MB-231 and TNBC BRCA1 5382insC mutated HCC1937 cells compared with non-tumorigenic epithelial breast MCF10A cells. The data includes DNA methylation, RNAseq, protein, phosphoproteomics, and histone post-translational modification. Data integration methods identified regulatory features from each omics method that had greater than 80% positive correlation within each TNBC subtype. Key regulatory features at each omics level were identified distinguishing the three cell lines and were involved in important cancer related pathways such as TGFβ signaling, PI3K/AKT/mTOR, and Wnt/beta-catenin signaling. We observed overexpression of PTEN, which antagonizes the PI3K/AKT/mTOR pathway, and MYC, which downregulates the same pathway in the HCC1937 cells relative to the MDA-MB-231 cells. The PI3K/AKT/mTOR and Wnt/beta-catenin pathways are both downregulated in HCC1937 cells relative to MDA-MB-231 cells, which likely explains the divergent sensitivities of these cell lines to inhibitors of downstream signaling pathways. The DNA methylation and RNAseq data is freely available via GEO GSE171958 and the proteomics data is available via the ProteomeXchange PXD025238.